Home/Pipeline/Zilebesiran (ALN-AGT)

Zilebesiran (ALN-AGT)

Hypertension

Phase 3Active (KARDIA trials)

Key Facts

Indication

Hypertension

Phase

Phase 3

Status

Active (KARDIA trials)

Company

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.

View full company profile

Therapeutic Areas

Rare Genetic Diseases Cardio-Metabolic Diseases Hepatic Infectious Diseases Central Nervous System (CNS) Diseases Ocular Diseases

Other Hypertension Drugs

Drug	Company	Phase	Status
Norliqva® (Amlodipine Oral Solution)	CMP Pharma	Approved	Marketed
Renal & Hepatic Denervation for Hypertension	Metavention	Feasibility	Active
MVD-1 (SANA)	Eolo Pharma	Discovery	Active
Peregrine System Renal Denervation	Ablative Solutions	Phase 3	Active
Hypertension Program	Closed Loop Medicine	Development	Active
GMRx2	George Medicines	Phase 3	Active
High Blood Pressure Study	West Coast Research	Phase 3/4	Active
DehydraTECH-CBD	Lexaria Bioscience	Human Clinical	Active